Are you Dr. Schuetz?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 22 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
62 Lexington St
Framingham, MA 01702Phone+1 774-279-0876Fax+1 508-872-4621
Summary
- Dr. Thomas Schuetz, MD is an oncologist in Framingham, Massachusetts. He is currently licensed to practice medicine in Massachusetts.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1998
Harvard Medical SchoolClass of 1993
Certifications & Licensure
MA State Medical License 1995 - 2019
Publications & Presentations
PubMed
- 156 citationsA phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).Joseph Muenzer, Muge Gucsavas-Calikoglu, Shawn E. McCandless, Thomas J Schuetz, Alan Kimura
Molecular Genetics and Metabolism. 2007-03-01 - 712 citationsOverall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate CancerPhilip W. Kantoff, T. Schuetz, Brent A. Blumenstein, L. Michael Glode, David L. Bilhartz
Journal of Clinical Oncology. 2010-03-01 - 18 citationsTargeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development.Weon-Kyoo You, Thomas J Schuetz, Sang Hoon Lee
Molecular Cancer Therapeutics. 2023-01-03
Press Mentions
Compass Therapeutics Announces That the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) Will Be Presented at the ASCO GI Cancers Symposium on January 20, 2023January 19th, 2023- Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor a (VEGF-A)January 20th, 2022
- CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 8th, 2021
- Join now to see all
